Eyepoint Pharmaceuticals (EYPT) to Release Quarterly Earnings on Wednesday

Key Points

• Eyepoint Pharmaceuticals is set to announce its Q2 2025 earnings on August 6th, with expectations of a loss of ($0.67) per share and projected revenue of $6.82 million.
• In the last quarter, the company reported earnings of ($0.65) per share, matching analyst estimates, alongside a surprising revenue of $24.50 million, versus an expected $8.84 million.
• Analysts have a consensus rating of "Moderate Buy" for Eyepoint Pharmaceuticals, with an average price target set at $25.67.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) will likely be posting its Q2 2025 quarterly earnings results before the market opens on Wednesday, August 6th. Analysts expect Eyepoint Pharmaceuticals to post earnings of ($0.67) per share and revenue of $6.82 million for the quarter.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.65) earnings per share for the quarter, meeting the consensus estimate of ($0.65). The business had revenue of $24.50 million for the quarter, compared to analyst estimates of $8.84 million. Eyepoint Pharmaceuticals had a negative return on equity of 54.27% and a negative net margin of 261.91%. On average, analysts expect Eyepoint Pharmaceuticals to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Eyepoint Pharmaceuticals Stock Down 1.1%

Shares of NASDAQ EYPT traded down $0.11 during midday trading on Friday, hitting $9.71. The stock had a trading volume of 502,236 shares, compared to its average volume of 611,722. The company has a fifty day moving average price of $9.27 and a 200 day moving average price of $7.36. The company has a market capitalization of $668.15 million, a price-to-earnings ratio of -4.03 and a beta of 1.73. Eyepoint Pharmaceuticals has a 1-year low of $3.91 and a 1-year high of $13.98.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. Mizuho dropped their price objective on Eyepoint Pharmaceuticals from $30.00 to $26.00 and set an "outperform" rating on the stock in a report on Friday, May 16th. Chardan Capital lowered their price target on Eyepoint Pharmaceuticals from $33.00 to $27.00 and set a "buy" rating for the company in a report on Thursday, May 8th. HC Wainwright reiterated a "buy" rating and issued a $22.00 price target on shares of Eyepoint Pharmaceuticals in a report on Thursday, May 29th. Finally, Royal Bank Of Canada began coverage on Eyepoint Pharmaceuticals in a report on Tuesday, June 17th. They issued an "outperform" rating and a $28.00 price target for the company. One equities research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. According to data from MarketBeat, Eyepoint Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $25.67.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.